Please let me know which of these studies that you are interested in reading, and I will be happy to

hopeful and optimistic
hopeful and optimistic Member Posts: 2,346 Member
in Prostate Cancer #1

Please let me know which of these studies that you are interested in reading, and I will be happy to post, or you can register to the site, either one is fine with me...I am happy to post the abstracts for any studies that you select

Prostate Cancer

ASCO 2013 - Poster: The genomic relationship among matched prostate cancer foci
ASCO 2013 - Poster: Safety of radium-223 dichloride with docetaxel in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium study
ASCO 2013 - Poster: Prospective evaluation of testosterone (T) recovery and PSA relapse following 18 months of androgen deprivation (ADT) after prostatectomy (RP): Results from the Tax-3501 trial
ASCO 2013 - Poster: An exploratory analysis of bone scan lesion area, circulating tumor cell change, pain reduction, and overall survival in patients with castration-resistant prostate cancer treated with cabozantinib
ASCO 2013 - Podcast: Prospective evaluation of testosterone (T) recovery and PSA relapse following 18 months of androgen deprivation (ADT) after prostatectomy (RP): Results from the TAX-3501 trial
ASCO 2013 - Podcast: The genomic relationship among matched prostate cancer foci
ASCO 2013 - Podcast: Evidence for a field effect in early prostate cancer (PCa): Gene expression profiles in normal-appearing prostate tissue (NT) adjacent to tumor (T) as predictors of clinical outcome
Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement - Abstract
Critical evaluation of MRI-targeted TRUS-guided transperineal fusion biopsy for detection of prostate cancer - Abstract
Early post-operative urinary and sexual function predicts functional recovery at one year following prostatectomy - Abstract
Prostate cancer overdiagnosis and overtreatment - Abstract
Genetic markers associated with early cancer-specific mortality following prostatectomy - Abstract
Comparison of 3 different postimplant dosimetry methods following permanent (125)I prostate seed brachytherapy - Abstract
Quality of life after prostate cancer treatments in patients comparable at baseline - Abstract
Screening for prostate cancer in New Zealand general practice - Abstract
Dormancy in solid tumors: Implications for prostate cancer - Abstract
Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate - Abstract
Consumption of fish products across the lifespan and prostate cancer risk - Abstract
A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer - Abstract
Imaging treated prostate cancer - Abstract
Multiparametric MRI of prostate cancer: An update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer - Abstract
Evaluation of serum calcium as a predictor of biochemical recurrence following salvage radiation therapy for prostate cancer - Abstract
Ultrasound elastography of the prostate: State of the art - Abstract
The role of prostate-specific antigen in light of new scientific evidence - Abstract
Automatic prostate tracking and motion assessment in volumetric modulated arc therapy with an electronic portal imaging device - Abstract
Decision regret in men undergoing dose-escalated radiation therapy for prostate cancer - Abstract
Socioeconomic variation and prostate specific antigen testing in the community: A UK- based population study - Abstract
The dilemma of localizing disease relapse after radical treatment for prostate cancer: Which is the value of the actual imaging techniques? - Abstract
Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: Long-term outcomes - Abstract
Multiparametric magnetic resonance imaging of prostate cancer - Abstract
The diagnostic value of conventional MRI in the differentiation of malignant tumor from benign lesion in prostatic peripheral zone - Abstract
Acute toxicity profile in prostate cancer with conventional and hypofractionated treatment - Abstract
Focal brachytherapy for selected low-risk prostate cancers: A pilot study - Abstract
Prevalence of patients with nonmetastatic prostate cancer on androgen deprivation therapy in the United States - Abstract
Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging-prompted areas following multiple failed biopsies - Abstract
Interstitial hyperthermia of the prostate in combination with brachytherapy: An evaluation of feasibility and early tolerance - Abstract
Perineural invasion and TRUS findings are complementary in predicting prostate cancer biology - Abstract
Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy - Abstract
PET imaging in prostate cancer: Focus on prostate-specific membrane antigen - Abstract
Minireview: Androgen metabolism in castration-resistant prostate cancer - Abstract
Magnetic resonance imaging for prostate cancer clinical application - Abstract
Prostate HistoScanning: A screening tool for prostate cancer? - Abstract
Assessment of screenees' knowledge on prostate cancer: Results of a questionnaire using the Fact Sheet - Abstract
Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer - Abstract
Oncological outcome after primary prostate cryoablation compared with radical prostatectomy: A single-centre experience - Abstract
Radiation therapy modalities in prostate cancer - Abstract
Bone metastases and bone loss medical treatment in prostate cancer patients - Abstract
Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol - Abstract
Focal ablation of prostate cancer: Four roles for magnetic resonance imaging guidance - Abstract
Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer - Abstract
Pain questionnaire performance in advanced prostate cancer: Comparative results from two international clinical trials - Abstract
Advancing precision medicine for prostate cancer through genomics - Abstract
The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses - Abstract




Advanced Prostate Cancer

ASCO 2013 - Podcast: Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011
ASCO 2013 - Podcast: Long-term safety and efficacy analysis of abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer without prior chemotherapy (COU-AA-302)
ASCO 2013 - Slide Lecture: Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302
ASCO 2013 - Slide Presentation: Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302
ASCO 2013 - Poster: Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302
ASCO 2013 - Poster: Long-term safety and efficacy analysis of abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer without prior chemotherapy (COU-AA-302)
Podcast: Castration-resistant prostate cancer: AUA Guideline 2013 commentary, by E. David Crawford, MD
AUA 2013 - Slide Lecture: Introducing a new option before chemotherapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
Targeting bone physiology for the treatment of metastatic prostate cancer - Abstract
Researchers identify novel class of drugs for prostate cancers
Enzalutamide: An evidence-based review of its use in the treatment of prostate cancer - Abstract
Systemic therapy in men with metastatic castration-resistant prostate cancer: A systematic review - Abstract
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer - Abstract
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide - Abstract




Prostate Cancer Immunotherapy







A message to our readers:

During the past 10 years, UroToday has created – and continues to grow – a truly unique and comprehensive database of urologic content. While we pride ourselves in the ability to provide our readers with free access to over 60,000 pages of content, we now require that all guests be registered and logged on before proceeding to our online resources and archive.

We invite you to take a moment to register. After that, you may simply log on with your user name and password whenever you visit our site.
 

 

Discussion Boards